Qdenga: a vaccine for dengue but not a silver bullet
The Hindu
India's first dengue vaccine, Qdenga, offers hope for reducing severe cases, yet challenges remain in addressing all virus serotypes.
India’s long wait for a dengue vaccine may finally be coming to an end. Takeda’s tetravalent dengue vaccine, TAK-003 (called ‘Qdenga’), recently received clearance from the Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI) for use among individuals aged 4 to 60 years. This marks a significant milestone in the country’s fight against a disease that causes millions of infections and thousands of hospitalisations every year, especially among children.
While India has not experienced a large nationwide dengue surge in the past year, the disease remains endemic, with substantial transmission and a long-term rising trend. For decades, dengue control in India relied almost entirely on vector control measures such as eliminating mosquito breeding sites, insecticide use, and public awareness campaigns. While essential, these strategies have had limited success in preventing recurring outbreaks. The arrival of a vaccine, therefore, represents a shift from a reactive to a more preventive approach.
TAK-003 comes with several advantages. It has been evaluated in large global trials involving more than 28,000 participants and has already been approved in more than 40 countries. Importantly, unlike an earlier dengue vaccine, it does not require pre-vaccination screening to determine prior dengue infection, making it simpler to use in real-world settings. The vaccine has also demonstrated good safety and, crucially, strong protection against severe dengue and hospitalisation — both outcomes that matter the most in clinical practice.
In a country like India, where healthcare systems are often stretched during dengue seasons, even a modest reduction in the number of severe cases could have a substantial impact. Fewer hospital admissions, reduced intensive care burden, and lower mortality in children and adolescents would all represent meaningful gains.
However, it is equally important to recognise what this vaccine can and cannot achieve. Dengue is caused by four closely related but distinct viruses, known as serotypes (DENV-1 to DENV-4). Immunity to one serotype does not guarantee protection against the others, and in some cases, can even predispose an individual to more severe disease upon subsequent infection. This makes developing a vaccine for dengue uniquely challenging: an effective vaccine must provide balanced protection against all four serotypes.
Herein lies a key limitation of TAK-003. While it performs very well against the DENV-2 serotype, since it was developed on the DENV-2 backbone, and reasonably well against DENV-1, its effectiveness against DENV-3 and DENV-4 appears to be lower — particularly in individuals who have not previously been infected with dengue.
